Health & Science

Synchron Pauses Clinical Trials for Second-Generation Brain Implant

· GlobeWire Daily Science Desk · Source: www.wired.com

2 min read

Key takeawaysBrain-computer interface developer Synchron has voluntarily paused enrollment in its multi-site clinical trials for a new second-generation brain implant. This decision follows reports that the device, a wireless iteration of the company’s 'Stentrode' system, has not met performance expectations during initial use.
Synchron Pauses Trials of Its Brain Implant Due to Performance Issues

Image: Emily Mullin · Photo source · Resized and letterboxed to 16:9; no AI generation

Brain-computer interface developer Synchron has voluntarily paused enrollment in its multi-site clinical trials for a new second-generation brain implant. This decision follows reports that the device, a wireless iteration of the company’s 'Stentrode' system, has not met performance expectations during initial use.

The Technical Issue

According to company statements, the pause stems from a performance issue involving the 'lead'—the cable responsible for carrying signals from the Stentrode to the implanted electronics. Synchron clarifies that:

  • The issue is limited to the cable design and not the Stentrode device itself.
  • No safety issues related to the device have been identified.
  • The action was taken by the company and was not mandated by the FDA.

Strategic Changes and Future Outlook

In response to these findings, Synchron is bringing the lead design and manufacturing processes in-house. The company is currently undergoing a restructuring process, which includes shifting its development focus toward a new team in San Diego.

Looking ahead, the company plans to:

  • Upgrade the entire Stentrode system hardware.
  • Resume trial enrollment once upgrades are completed.
  • Continue supporting existing participants who use the first-generation device.

These clinical trials are a crucial step toward obtaining FDA marketing approval for the Stentrode. While the current pause impacts progress, CEO Tom Oxley maintains confidence in the technology's potential as a future therapy. The company continues to develop a separate, undisclosed device designed to reach beyond blood vessels to access multiple brain regions simultaneously.

Share this article
Read the original source: Synchron Pauses Trials of Its Brain Implant Due to Performance Issues

AI-assisted reporting; source claims are attributed and have not been independently verified.

About the author

GlobeWire Daily Science Desk — AI-assisted news based on attributed published sources.

More to read